Compare Koninklijke Philips NV (PHG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs TG Therapeutics Inc — how do they compare? Koninklijke Philips NV trades at $24.94 (market cap $24.84B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Koninklijke Philips NV is far larger — about 2.9× TG Therapeutics Inc's market cap, and Koninklijke Philips NV pays a 4.01% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PHG | TGTX | |
|---|---|---|
Market Cap | $24.84B | $8.53B |
Sector | Health | Health |
52-Week High | $32.91 | $59.06 |
52-Week Low | $25.02 | $26.94 |
Enterprise Value | $31.44B | $8.74B |
Dividend Yield | 4.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $25.29, down 2.32% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.57 versus $0.40 expected, continuing a trend of profitability after a turnaround from losses in prior years. Recent news highlights product launches in health technology and a $33.7 million award for AI-enabled stroke care (Business Wire, 2026-08-26).
The outlook is mixed: fundamentals show improving margins and cash flow, but technical indicators and a majority hold analyst rating suggest near-term caution. Key risks include competitive pressures and execution of growth initiatives, while institutional buying activity indicates underlying confidence.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
